Lysosome Regulation of Exosome Release and Function in Arterial Smooth Muscle
溶酶体对动脉平滑肌中外泌体释放和功能的调节
基本信息
- 批准号:10092204
- 负责人:
- 金额:$ 48.84万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-01-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:AbbreviationsAddressAgonistAlkaline PhosphataseAnimalsAortaApplications GrantsArterial Fatty StreakArteriesAutophagocytosisBindingCRISPR/Cas technologyCalciumCalmodulinCell ProliferationCell membraneCellsCeramidesCodeCollagenCoronaryCoronary ArteriosclerosisCoronary arteryDefectDepositionDevelopmentEarly EndosomeEnzymesExcretory functionExtracellular MatrixFarber&aposs lipogranulomatosisFunctional disorderFutureGene DeletionGenesHumanImageInjuryKnockout MiceLinkLipidsLysosomesMedialMediatingMembrane ProteinsMetabolismMicroRNAsMolecularMultivesicular BodyMusMuscle ProteinsMyocardial InfarctionPathogenesisPathogenicityPathologicPhenotypePhysiologicalPlayPreventionProcessProductionProteinsRecyclingRegulationResearchRoleSignal PathwaySignal TransductionSmooth MuscleSmooth Muscle MyocytesSphingolipidsSphingomyelinsSphingosineStimulusTestingTransmission Electron MicroscopyVacuolar Protein SortingVascular calcificationVesiclebasecalcificationcell dedifferentiationexosomeextracellular vesiclesgalactosylgalactosylglucosylceramidaseinsightinterstitialknockout genelate endosomemineralizationnanoparticlenovel therapeuticsosteogenicpatch clamppreventprogramspromoterreceptorsensortherapeutic targettraffickingvesicular release
项目摘要
Project Summary
Exosomes are from the intraluminal vesicles (ILV) of multivesicular bodies (MVBs) produced via endocytic
process. Mature MVBs can fuse with lysosomes to deliver their contents for degradation and recycling or fuse
with the plasma membrane where ILVs are released as exosomes. Recent studies have indicated that
enhanced exosome excretion in arterial smooth muscle cells (SMCs) is an essential mechanism triggering or
promoting calcifying nidus formation and extracellular matrix (ECM) mineralization in the arterial wall under
different pathological conditions. However, little is known so far how MVB fate and exosome excretion are
controlled by lysosomes in SMCs and whether lysosomal dysfunction increases exosome excretion from SMCs
to activate or accelerate vascular calcification process. The present grant proposal will test a central
hypothesis that lysosomal acid ceramidase (AC)-mediated sphingolipid metabolism plays a crucial role in the
control of lysosome trafficking or fusion to MVBs and subsequent exosome excretion, maintaining the normal
phenotype and function of SMCs. AC gene defect or functional deficiency may disturb lysosome degradation of
MVBs, increasing exosome excretion and resulting in calcifying nidus formation and ultimate vascular
calcification under pathological conditions. To test this hypothesis, three Specific Aims are proposed. Specific
Aim 1 will determine whether exosome excretion in arterial SMCs is fine controlled by lysosomal AC activity
and whether the deficiency of this AC regulation causes arterial calcification in smooth muscle-specific AC
gene knockout mice (Asah1fl/fl/SMcre) with analysis of exosomes, SMC phenotypes, and calcification in the
arterial wall and cultured coronary arterial SMCs. Specific Aim 2 attempts to test whether lysosomal AC-
mediated sphingolipid signaling regulates lysosome trafficking to and fusion with MVBs to limit exosome
excretion from SMCs with gene deletion (Asah1fl/fl/SMcre), CRISPR-Cas9 gene editing, and SM22α promoter-
driven gene rescuing. In Specific Aim 3, we will address whether the AC regulation of lysosome trafficking or
fusion to MVBs is attributed to its action on lysosomal TRPML1 channel activity and associated Ca2+ release
using patch clamping of isolated lysosomes and lysosome-specific Ca2+ imaging with GCaMP3-ML as an
indicator. To our knowledge, these proposed studies will represent the first effort to investigate the lysosome
regulation of exosome excretion from SMCs and associated pathogenic role in vascular calcification. The
findings will provide new insights into the pathogenesis of arterial calcification and identify lysosomal AC as a
therapeutic target for prevention or treatment of vascular calcification.
项目摘要
外泌体来自通过内吞植物的内部蔬菜(ILV)(MVB)
过程。成熟的MVB可以与溶酶体融合,以递送含量以降解和回收或保险丝
与质膜一起以外泌体释放的ILV。最近的研究表明
动脉平滑肌细胞(SMC)中增强的外泌体排泄是一种基本机制触发或
在动脉壁中促进钙化的Nidus形成和细胞外基质(ECM)矿化
不同的病理条件。但是,到目前为止,鲜为人知的MVB命运和外泌体排泄是如何
由SMC中的溶酶体控制以及溶酶体功能障碍是否增加了SMC的外泌体排泄
激活或加速血管钙化过程。目前的赠款提案将测试中央
假设溶酶体酸神经酶(AC)介导的鞘脂代谢在
控制MVB的溶酶体运输或融合以及随后的外泌体排泄,保持正常
SMC的表型和功能。 AC基因缺陷或功能缺陷可能会干扰溶酶体降解的
MVB,增加外泌体排泄并导致钙化Nidus形成和最终血管
病理条件下的钙化。为了检验这一假设,提出了三个具体目标。具体的
AIM 1将确定动脉SMC中的外泌体排泄是否受溶酶体AC活性的控制
以及该AC调节的缺乏是否导致平滑肌特异性AC中的动脉计算
基因敲除小鼠(ASAH1FL/FL/SMCRE),分析外泌体,SMC表型和钙化
动脉壁和培养的冠状动脉SMC。特定的目标2尝试测试是否溶酶体AC-
介导的鞘脂信号传导调节溶酶体贩运和与MVB的融合以限制外泌体
具有基因缺失(ASAH1FL/FL/SMCRE),CRISPR-CAS9基因编辑和SM22α启动子的SMC的排泄
驱动的基因营救。在特定的目标3中,我们将解决溶酶体贩运的AC法规还是
与MVB的融合归因于其对溶酶体TRPML1通道活动的作用和相关的Ca2+释放
使用分离的溶酶体和溶酶体特异性Ca2+成像的斑块夹具用GCAMP3-ML作为一个
指标。据我们所知,这些拟议的研究将代表研究溶酶体的第一个努力
调节SMC的外泌体排泄和血管钙化中相关的致病作用。这
发现将为动脉计算的发病机理提供新的见解,并将溶酶体AC识别为A
预防或治疗血管钙化的治疗靶标。
项目成果
期刊论文数量(56)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Concentration-Dependent Diversifcation Effects of Free Cholesterol Loading on Macrophage Viability and Polarization.
- DOI:10.1159/000430365
- 发表时间:2015
- 期刊:
- 影响因子:0
- 作者:Xu X;Zhang A;Li N;Li PL;Zhang F
- 通讯作者:Zhang F
Enhancement of dynein-mediated autophagosome trafficking and autophagy maturation by ROS in mouse coronary arterial myocytes.
- DOI:10.1111/jcmm.12326
- 发表时间:2014-11
- 期刊:
- 影响因子:5.3
- 作者:Xu M;Li XX;Chen Y;Pitzer AL;Zhang Y;Li PL
- 通讯作者:Li PL
Oxidative stress triggers Ca-dependent lysosome trafficking and activation of acid sphingomyelinase.
- DOI:10.1159/000341460
- 发表时间:2012
- 期刊:
- 影响因子:0
- 作者:Li X;Gulbins E;Zhang Y
- 通讯作者:Zhang Y
Regulation of dynein-mediated autophagosomes trafficking by ASM in CASMCs.
- DOI:10.2741/4415
- 发表时间:2016-01-01
- 期刊:
- 影响因子:0
- 作者:Xu M;Zhang Q;Li PL;Nguyen T;Li X;Zhang Y
- 通讯作者:Zhang Y
Regulation of exosome release by lysosomal acid ceramidase in coronary arterial endothelial cells: Role of TRPML1 channel.
- DOI:10.1016/bs.ctm.2022.09.002
- 发表时间:2022
- 期刊:
- 影响因子:0
- 作者:Li, Guangbi;Huang, Dandan;Li, Pengyang;Yuan, Xinxu;Yarotskyy, Viktor;Li, Pin-Lan
- 通讯作者:Li, Pin-Lan
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PinLan Li其他文献
PinLan Li的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PinLan Li', 18)}}的其他基金
Lysosome dysfunction in podocytopathy and associated hypertension
足细胞病和相关高血压中的溶酶体功能障碍
- 批准号:
9792379 - 财政年份:2018
- 资助金额:
$ 48.84万 - 项目类别:
Lysosome dysfunction in podocytopathy and associated hypertension
足细胞病和相关高血压中的溶酶体功能障碍
- 批准号:
10461007 - 财政年份:2018
- 资助金额:
$ 48.84万 - 项目类别:
Lysosome dysfunction in podocytopathy and associated hypertension
足细胞病和相关高血压中的溶酶体功能障碍
- 批准号:
10218151 - 财政年份:2018
- 资助金额:
$ 48.84万 - 项目类别:
Lysosome Trafficking Dysregulation of Arterial Myocytes in Atherogenesis
动脉粥样硬化中动脉肌细胞的溶酶体运输失调
- 批准号:
9097883 - 财政年份:2015
- 资助金额:
$ 48.84万 - 项目类别:
Renomedullary metabolism of anandamide and blood pressure regulation
anandamide 的肾髓代谢与血压调节
- 批准号:
9054518 - 财政年份:2015
- 资助金额:
$ 48.84万 - 项目类别:
Lysosome Trafficking Dysregulation of Arterial Myocytes in Atherogenesis
动脉粥样硬化中动脉肌细胞的溶酶体运输失调
- 批准号:
9201339 - 财政年份:2015
- 资助金额:
$ 48.84万 - 项目类别:
Lysosome Trafficking Dysregulation of Arterial Myocytes in Atherogenesis
动脉粥样硬化中动脉肌细胞的溶酶体运输失调
- 批准号:
9002899 - 财政年份:2015
- 资助金额:
$ 48.84万 - 项目类别:
Epigenetic Regulation of Lysosomal Ceramide Signaling and Function in Arterial Myocytes: Role of Kmt6 Gene
动脉肌细胞溶酶体神经酰胺信号和功能的表观遗传调控:Kmt6 基因的作用
- 批准号:
10450193 - 财政年份:2014
- 资助金额:
$ 48.84万 - 项目类别:
Renomedullary metabolism of anandamide and blood pressure regulation
anandamide 的肾髓代谢与血压调节
- 批准号:
8852753 - 财政年份:2014
- 资助金额:
$ 48.84万 - 项目类别:
Lysosome Trafficking Dysregulation of Arterial Myocytes in Atherogenesis
动脉粥样硬化中动脉肌细胞的溶酶体运输失调
- 批准号:
8842197 - 财政年份:2014
- 资助金额:
$ 48.84万 - 项目类别:
相似国自然基金
时空序列驱动的神经形态视觉目标识别算法研究
- 批准号:61906126
- 批准年份:2019
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
本体驱动的地址数据空间语义建模与地址匹配方法
- 批准号:41901325
- 批准年份:2019
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
大容量固态硬盘地址映射表优化设计与访存优化研究
- 批准号:61802133
- 批准年份:2018
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
IP地址驱动的多径路由及流量传输控制研究
- 批准号:61872252
- 批准年份:2018
- 资助金额:64.0 万元
- 项目类别:面上项目
针对内存攻击对象的内存安全防御技术研究
- 批准号:61802432
- 批准年份:2018
- 资助金额:25.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Glutathionylated Products of Radical-Induced Lipid Oxidation in Inflammatory Disease
炎症性疾病中自由基诱导的脂质氧化的谷胱甘肽化产物
- 批准号:
10736332 - 财政年份:2023
- 资助金额:
$ 48.84万 - 项目类别:
Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk
磷脂酰丝氨酸阻断纳米颗粒可改善抗血栓形成并降低出血风险
- 批准号:
10598788 - 财政年份:2023
- 资助金额:
$ 48.84万 - 项目类别:
Involvement of microglial α7AChR in binge alcohol modulation of gut dysbiosis
小胶质细胞α7AChR参与酗酒调节肠道菌群失调
- 批准号:
10705750 - 财政年份:2022
- 资助金额:
$ 48.84万 - 项目类别:
Involvement of microglial α7AChR in binge alcohol modulation of gut dysbiosis
小胶质细胞α7AChR参与酗酒调节肠道菌群失调
- 批准号:
10527744 - 财政年份:2022
- 资助金额:
$ 48.84万 - 项目类别:
FrostBite-DMR - A new Drug-Free Approach for Treating Type 2 Diabetes Supplemental Request
FrostBite-DMR - 一种治疗 2 型糖尿病的新无药方法补充请求
- 批准号:
10748325 - 财政年份:2022
- 资助金额:
$ 48.84万 - 项目类别: